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Abstract
Reimbursement information for public and private payers has long been available. However, 
information about charges—the amounts that providers request before payments are negotiated—
has been scarce, particularly for outpatient care. Using the new Medicare Provider Utilization and 
Payment Data Public Use File and other sources, we evaluated physician charges, reimbursements 
by Medicare and large private health plans, and expected patient cost sharing for outpatient 
oncology care. In 2012 the average Medicare reimbursement for chemotherapy was 39.6 percent 
of charges; for private insurance, the share was 55.7 percent. Uninsured patients faced potential 
prices for chemotherapy that were 2–43 times as much as the total Medicare allowed amount and 
2–5 times as much as the private insurance allowed amount. Charges for outpatient chemotherapy 
and office visits were substantially higher than insurer-reimbursed amounts, which is consistent 
with previous evidence about hospital charges. The charges for outpatient services underscore the 
pressure that the current system places on people who are least able to pay. Encouraging rational 
pricing for health care services will be an important step toward ensuring access to care for 
everyone.
In April 2014 the Centers for Medicare and Medicaid Services (CMS) released the Medicare 
Provider Utilization and Payment Data Public Use File as part of a national effort to increase 
transparency in the health care system.[1,2] These publicly available data provide a 
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comprehensive look at charges and reimbursements for physician services delivered to 
Medicare beneficiaries.
Some physicians have expressed concerns about the potential misuse or misinterpretation of 
these data.[3–5] However, little has been said about their value for increasing our 
understanding about the fee-for-service health system more broadly. Although 
reimbursement information about public and private payers has long been available, 
information about charges—particularly for outpatient care—has been scarce.[6–8]
Physician and hospital charges—the full amounts requested before payment discounts are 
applied—can be considered a proxy for the market price of health care for patients without 
the power to negotiate reductions. Reimbursed amounts, in contrast, tend to represent 
discounted rates obtained as a result of negotiations between insurers and providers, 
including individual providers, provider groups, and health care systems. As a result, health 
economists generally consider reimbursed amounts to represent the actual price of health 
care.
Medicare reimbursement rates are fixed. However, aside from regional adjustments, private 
insurance reimbursements may vary based on providers’ negotiating power.[9] For people 
with insurance, charges are simply prices shown on explanation of benefits statements. 
Charges appear unrelated to what the insurer or beneficiary pays, and they often vary 
dramatically across hospitals or practices.[6,10] Unfortunately, charges may also represent 
the potential price of health care services for uninsured patients who are unable to negotiate 
better rates.[11–13]
The new CMS public use data are being used primarily to understand the cost and use of 
health services among Medicare beneficiaries. However, the data can also be used to 
understand the fee-for-services reimbursement system more broadly. This includes 
determining the upper limits on what uninsured patients are charged for their care.
The number of uninsured patients is declining due to provisions in the Affordable Care Act 
(ACA). Nonetheless, many low-income people remain uninsured in states that have not 
expanded Medicaid eligibility to nondisabled adults with incomes at or below 138% of 
poverty. In these states low-income individuals will likely remain uninsured because they 
earn too much to be eligible for Medicaid and too little to be eligible for premium subsidies 
in the health insurance exchanges.[14] Others may not be able to afford the cost of coverage, 
even if they are eligible for subsidies.
For an uninsured patient, charges for medical services matter greatly, particularly when the 
patient is diagnosed with a serious illness. Not only are many uninsured patients living on 
low incomes, they are also ineligible to benefit from the ACA’s limits on out-of-pocket 
spending ($6,350 for an individual or $12,700 for a family in 2014).
Our objective was to summarize physician charges, reimbursements from Medicare and 
large private health plans, and expected patient cost sharing for oncology care delivered in 
outpatient physician office settings. We evaluated oncology care, including office visits and 
chemotherapy, because cancer is prevalent (more than 1.6 million Americans are expected to 
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be diagnosed in 2015 [15]) and most oncology care is delivered in outpatient physician 
office settings. Furthermore, chemotherapy reimbursements for Medicare patients are 
standardized (at the average sales price plus 6 percent). Thus, regional variations in 
reimbursements are less problematic for chemotherapy than [for other outpatient health 
services].
 Study Data And Methods
 Data Sources
We used two data sources. The first—the Medicare Physician and Other Supplier Public Use 
File—contains Medicare Part B noninstitutional claims for outpatient services and 
procedures delivered in community settings by physician and nonphysician practitioners 
with a valid National Provider Identification number. The database includes submitted 
charges and payments to providers, organized by the identification number, Healthcare 
Common Procedure Coding System (HCPCS) code, and place of service. To protect 
Medicare beneficiaries’ privacy, CMS excluded any aggregated records with ten or fewer 
beneficiaries.
The second—the Truven Health MarketScan Commercial Claims and Encounters database
—contains deidentified, patient-level health data including enrollment, inpatient and 
outpatient medical claims, and prescription drug claims. These data cover more than twenty 
million people annually who are enrolled in private insurance plans provided by 
approximately a hundred large or medium-size employers.
 Sample Selection
To make comparable estimates from each data source, we selected claims for infused 
chemotherapies (HCPCS codes J9XXX) and office visits (HCPCS codes 99203–05 and 
99213–15). To ensure that we were identifying oncology use, we required that claims be 
submitted by providers classified as oncologists, hematologists, or urologists. We excluded 
claims from regions outside of the contiguous United States.
We restricted private insurance claims to people ages 50–64 years because chemotherapy 
billing is based on unit charges that are related to patient size, which is unavailable in 
administrative claims. We assumed that patients ages 50–64 would receive doses that were 
more similar to doses for patients ages 65 and older than to doses for younger patients.
 Physician Charges And Payments By Medicare And Private Insurers
Cost-related data for 2012 were extracted from each data source. In the Physician and Other 
Supplier Public Use File, data are aggregated at the physician–procedure code level. Each 
physician–procedure code combination includes average physician charges per unit of 
chemotherapy or office visit; total Medicare allowed amounts, which were the total amounts 
paid by Medicare plus those for which the patient was liable; and the total amounts paid by 
Medicare.
We calculated the average chemotherapy charge per patient visit by multiplying the unit 
charge by the average number of units billed at each visit. This value represented the price 
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for the average dose of chemotherapy received across all beneficiary visits. To check the 
validity of these calculations, we also calculated doses assuming that the patient was an 
adult male of average height and weight (with a body surface area of 1.9 meters squared). 
This allowed us to verify that the doses we originally calculated as billed to Medicare were 
within the expected range for use in cancer treatment. Only one agent (fluorouracil) was 
outside of the expected range, with a dose approximately twice that of the average 
recommended dose.
For private insurance claims, chemotherapy reimbursements and out-of-pocket costs are 
provided as a total amount reimbursed instead of a per unit cost. The data include total 
reimbursed amounts (representing patient and health plan contributions) and amounts 
reimbursed by the health plan alone. The total minus the health plan reimbursement 
represents the amount that the patient is liable for.
Although physician submitted charges were available only within the Physician and Other 
Supplier Public Use File, we assumed that these charges represented prices set for services, 
regardless of payer.[16] We summarized private insurance claims at the patient-visit level for 
a single use of chemotherapy.
 Analysis
We described charges, insurance payments, and patient payments for chemotherapy and 
office visits for Medicare patients and privately insured patients. We calculated the patient 
liability for Medicare patients, privately insured patients, and uninsured patients by 
subtracting the reimbursed amount from the charged amount and assuming that the 
reimbursed amount was $0 for uninsured patients. We used this strategy to estimate the 
upper bound on the price for uninsured patients, assuming that they did not negotiate with 
the provider about the set charge amount.
We calculated the percentage of charges reimbursed by each payer by dividing the total 
reimbursed for the service by the submitted charges. We also evaluated the relative 
generosity of reimbursements across payers by dividing the privately insured reimbursed 
amount by the Medicare reimbursed amount. Finally, to evaluate patient out-of-pocket 
liability, we compared the proportion of the reimbursement owed by the patient for each 
service and payer to the submitted charges.
 Limitations
The currently available data represent charges and reimbursements only for 2012. It is 
unclear how charges might vary over time; understanding longitudinal patterns could 
provide greater insight. Further, charges are only available on the Medicare Physician and 
Other Supplier Public Use File and not within the private health insurance claims; we 
assume that charges submitted by the provider do not vary by payer type but are unable to 
test this assumption in our data.
In addition, our estimates do not account for premium payments made by insured patients, 
an ever-increasing portion of health care spending for individuals. Understanding this 
portion of the patient’s financial liability would make the costs of care for patients more 
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transparent. This is particularly important for people enrolled in high-deductible health 
plans.
 Study Results
 Charges And Insurance Reimbursements For Oncology Services
Mean physician charges for chemotherapy ranged from $59 per infusion (for 500 mg of 
fluorouracil) to $9,225 per infusion (for 10 mg of bevacizumab), with wide variability across 
providers (Exhibit 1). (The complete list of chemotherapy charges can be found in online 
Appendix Table 1.)[17] For example, the average charge for a single infusion of trastuzumab 
was $5,344, but the charge varied across providers (interquartile range: $3,889–$6,675; data 
not shown).
The average Medicare reimbursement for chemotherapy was 39.6 percent of charges (range 
across drugs: 2.4–54.0 percent). In contrast, the average private insurance reimbursement 
was 55.7 percent of charges (range: 20.0–61.1 percent). In many cases there were only 
modest differences in reimbursements between Medicare and private payers, with Medicare 
to private payer payment ratios ranging from 1.0 to 1.2 for nearly 60 percent of infusions. 
However, approximately one-third of the chemotherapy agents examined were reimbursed at 
much higher rates by private insurance than by Medicare (payment ratios: 2.5–11.7).
The mean charge for an oncology outpatient office visit of low complexity for a new patient 
was $198; the charge for a visit of high complexity was $391 (Exhibit 2). However, the 
charges varied across physicians. On average, Medicare-reimbursed physicians received 
48.0–51.1 percent of charges for office visits for new and established patients, and private 
insurer–reimbursed physicians received 60.7–64.7 percent of charges (data not shown).
 Patient Out-of-Pocket Liability
The average out-of-pocket liability for Medicare patients across all chemotherapy agents 
(assuming no supplemental coverage) was $238 and across all office visit types was $29 
(Exhibit 3). The average for privately insured patients was $85 and $36, respectively. For 
uninsured patients, however, the potential maximum out-of-pocket liability was 
approximately $2,872 for chemotherapy and $230 for office visits, assuming the patient’s 
bill reflected physician charges without discounts. Uninsured patients faced billed amounts 
for chemotherapy that were 2–43 times as much as the Medicare allowed amount and 2–5 
times as much as the private insurance allowed amount.
If uninsured patients were liable for the full charged amount, they would pay 9–200 times as 
much as Medicare-insured patients would pay out of pocket and 13–128 times as much as 
privately insured patients, depending on the chemotherapy agent used (Exhibit 3 and 
Appendix Table 2).[17] Similarly, for office visits, uninsured patients would be liable for 4–
9 times as much as insured patients, depending on the insurance type used for comparison. 
Privately insured patients tended to have lower out-of-pocket liability for chemotherapy and 
higher out-of-pocket liability for office visits, compared to Medicare beneficiaries.
Dusetzina et al. Page 5














We used data from the Medicare Physician and Other Supplier Public Use File and large 
employer-sponsored private health plans to estimate charges, reimbursements, and patient 
liability for chemotherapy and office visits delivered in outpatient office settings. Charges 
for outpatient chemotherapy and office visits were substantially higher than the amounts 
reimbursed by insurers, which is consistent with previous evidence about hospital charges.
[6,10–12,18]
In general, private insurers’ reimbursement to physicians was more generous than 
Medicare’s reimbursement, which is not surprising. We also found that the out-of-pocket 
liability for Medicare-insured beneficiaries was generally higher than that for privately 
insured beneficiaries.
These differences may be partially explained by privately insured patients (or their 
employers) paying higher premium payments (which we are unable to measure in our data) 
in exchange for lower out-of-pocket costs. It is also important to note that although Medicare 
beneficiaries are responsible for paying approximately 20 percent of the allowed amounts in 
copayments, many Medicare beneficiaries purchase supplemental coverage to assist with 
these out-of-pocket costs.
Importantly, patients who lack insurance and seek outpatient care may be financially liable 
for the charged amounts.[12,13,19] These patients face billed amounts for chemotherapy 
that are much higher than the amounts billed to either Medicare or private insurance.
Most previous data on differences between charges and negotiated rates paid by large 
insurers have focused on hospital pricing, where it has been suggested that charges are not 
connected to underlying costs or market prices.[18] Whether this is true for outpatient 
services is unknown.
It is also unclear whether or to what extent patients negotiate to reduce their prices for 
outpatient care or if uninsured patients are initially offered lower prices, compared to insured 
patients. Some limited evidence suggests that uninsured patients are not initially offered 
lower prices. For example, in one study the median price quoted for a hypothetical new 
patient visit for uninsured patients was $154 (inflation-adjusted to 2012 dollars).[20] This is 
similar to charges of $162 in the Medicare Provider Utilization and Payment Data Public 
Use File for new patient visits of low complexity delivered by internal medicine or family 
medicine practitioners (data not shown).
In one of the few studies that documented prices charged to uninsured and privately insured 
patients in the outpatient setting, researchers found that 87 percent of uninsured patients 
were billed more than insured patients using the same services, and that 23 percent were 
billed 200 percent more than their insured counterparts.[19] The researchers also found that 
the average price paid by uninsured patients reflected a mix of patients who paid nothing 
and patients who overpaid (relative to private insurance). In that study, almost 10 percent of 
uninsured patients ultimately paid twice the amount paid by insured patients who received 
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the same services. A large proportion of patients who did not pay had their bills sent to 
collection agencies.[19]
In the hospital setting, a separate study found that uninsured hospitalized patients were 
charged two and a half times more than patients covered by major insurance companies and 
three times more than patients covered by Medicare or Medicaid.[12] Our analysis of the 
newly released CMS public use data found consistent results. But [the gap between 
uninsured and insured patients] is more extreme if we assume that charges represent 
uninsured patient prices for those people who do not negotiate with their providers.
It is unclear what steps physicians take to limit costs for uninsured patients who access the 
health care system. One survey suggested that 65 percent of primary care doctors reported 
reducing their fees, charging nothing, or setting up payment plans for patients who had 
difficulty paying.[21] Additionally, some outpatient service providers offer “volunteer” or 
charity care services to ensure access to [health care services] for patients who cannot afford 
treatment.[22]
However, declining insurance reimbursements and rising operating costs have been 
previously cited as contributing to a decline in the supply of such services.[23] Many 
oncologists reported either that their patients had difficulty paying for their medications or 
that they considered costs in their treatment decisions, but most reported referring patients to 
a third party for billing-related issues.[24] Even if the price for health services are ultimately 
moderated or negotiated, this is an uncertainty for many patients and may create financial 
hardships and barriers to care for uninsured or underinsured individuals.
In addition to the concerns related to price discrimination according to the insurance status 
of those receiving care, some evidence from ambulatory care settings suggests that 
uninsured patients may even have difficulty scheduling appointments if they indicate their 
interest in payment plans or reduced payments.[20,25] In one study in which research 
assistants called randomly selected ambulatory clinics posing as new patients who had been 
seen in an emergency department and who were in need of urgent follow-up appointments, 
60 percent of callers claiming to be uninsured who initially obtained appointments had their 
appointments canceled if they requested an opportunity to pay $20 in cash and arrange for 
future payment of the balance.[25] Notably, in these studies appointment rates were similar 
for insured and uninsured callers if the uninsured callers noted their intention to pay cash for 
the full visit price at the time of service.
Compared with similar insured patients, twice as many uninsured patients indicated that they 
had trouble paying their medical bills, and uninsured patients were three times more likely to 
report being unable to pay for basic necessities due to their medical bills.[26] Given the high 
costs of treating cancer,[27,28] it is no surprise that 25 percent of uninsured cancer patients 
said that costs affected their decisions about treatment.[29]
Prior to the implementation of the ACA, it was estimated that approximately 10–15 percent 
of cancer patients under the age of sixty-five were uninsured.[30,31] Although the number 
of uninsured Americans is expected to decline as a result of the ACA, estimates suggest that 
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up to thirty million people may remain uninsured following full implementation of the act.
[32]
As of January 2015, fifteen states have chosen to not expand Medicaid, and seven other 
states are debating the expansion.[33] Low-income people in states not expanding Medicaid 
may face substantial financial liability when they receive health services, including the 22 
percent of currently uninsured cancer survivors who will fall into this coverage gap.[31]
 Conclusion
The release of the Medicare Provider Utilization and Payment Data Public Use File 
represents a first step toward increasing the transparency of health care pricing in the United 
States. The data include Part B physician and supplier charges, with limited information on 
hospital outpatient and inpatient care. Given the recent market consolidation among many 
private practices into hospital systems, it will be important for CMS to increase the 
availability of information in the hospital outpatient and inpatient files beyond the minimum 
billing codes provided previously (for the hundred most common inpatient and thirty most 
common outpatient services).
Patients receiving care from hospital-affiliated clinics are likely to have even higher cost-
sharing requirements because they must pay facility fees as well as physician fees. Indeed, 
this issue may become even more pressing as private insurance plans begin to rein in their 
reimbursements for care delivered in hospital outpatient settings.[34]
Now that data on physician-delivered outpatient charges are available, it will be important to 
understand how these charges are determined and whether they are related to costs and 
private insurer reimbursements. Physician charges for outpatient services underscore the 
pressure that the current system places on the people who are least able to pay. Encouraging 
rational and transparent pricing for health care services is an important step toward ensuring 
access to care for everyone.
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